These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2727909)

  • 1. [Functional status of thrombocytes and the anti-aggregative activity of the vascular wall in dyslipoproteinemias and ischemic heart disease].
    Mikhailova IA; Lipovetskiĭ BM; Magracheva EIa; Gurevich VS
    Ter Arkh; 1989; 61(2):101-4. PubMed ID: 2727909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of type IIa, IIb and IV-hyperlipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life.
    Strobl-Jäger E; Widhalm K; Sinzinger H
    Prostaglandins Leukot Med; 1986 Nov; 25(1):39-47. PubMed ID: 3540998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased in vitro platelet aggregation in hypertriglyceridemias.
    Riess H; Merk W; Falkner C; Hiller E
    Thromb Res; 1986 Feb; 41(3):281-9. PubMed ID: 3705010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithrombogenic activity of the vascular wall, hemostasis, and rheological characteristics of blood in patients with unstable angina pectoris and various types of hyperlipoproteinemia].
    Kirichuk VF; Voskoboĭ IV
    Ter Arkh; 2000; 72(12):47-50. PubMed ID: 11201832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of fish oils on plasma lipid risk factors and esterified fatty acids in primary hyperlipoproteinemia].
    Zák A; Zeman M; Tvrzická E
    Sb Lek; 1997; 98(3):213-24. PubMed ID: 9601814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
    Goubran F; Maklady F; Saad M; el-Ashry M
    Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheological properties and membrane fluidity of red blood cells and platelets in primary hyperlipoproteinemia.
    Muller S; Ziegler O; Donner M; Drouin P; Stoltz JF
    Atherosclerosis; 1990 Aug; 83(2-3):231-7. PubMed ID: 2242099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study of phospholipids in primary hyperlipoproteinemias].
    Kuczyńska K
    Pol Arch Med Wewn; 1979 Jul; 62(1):29-40. PubMed ID: 503884
    [No Abstract]   [Full Text] [Related]  

  • 11. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased number of PGD2 binding sites on platelets from patients with type IIa hyperlipoproteinemia.
    Abbate R; Modesti PA; Fortini A; Lombardi A; Matucci M; Gensini GF; Neri Serneri GG; Fellin R; Valerio G; Crepaldi G
    Atherosclerosis; 1985 Feb; 54(2):167-75. PubMed ID: 3857047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fatty acid metabolism in primary hyperlipoproteinemia (HLP) (author's transl)].
    Reuter W
    Dtsch Z Verdau Stoffwechselkr; 1979; 39(3):124-9. PubMed ID: 520271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
    Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
    Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
    [No Abstract]   [Full Text] [Related]  

  • 17. Altered platelet deformability in patients with type IIa and type IV hyperlipoproteinemia.
    Smith CM; Burris SM; Hunninghake DB; White JG
    Am J Hematol; 1988 Apr; 27(4):247-52. PubMed ID: 3354559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Blood and plasma hyperviscosity in primary hyperlipidemia].
    Ozanne P; Boudart D; Mainard F; Lefebvre J; Grolleau JY
    Rev Med Interne; 1984 Mar; 5(1):29-33. PubMed ID: 6718836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Examination of cortisol and insulin levels in serum of patients with primary hyperlipoproteinemia and phenotype IIa and IIb during lovastatin treatment].
    Idzior-Waluś B
    Przegl Lek; 1992; 49(11):365-8. PubMed ID: 1306568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.